Skip to content
MarketNewsAPI
Live news Screener Coverage Pricing Docs REST API WebSocket API MCP server Company Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
TECK$59.05+0.15(+0.25%)Teck Provides Update on Highland Valley Copper Operations[3:18:56 PM ET]AXON$422.00+7.40(+1.78%)Axon Announces Body 5: Next-Generation Camera Built for the AI Era Axon (Nasdaq: AXON), the global leader in public safety technology, today announced Axon Body 5, its newest body-worn camera designed to bring more...[1:00:00 PM ET]PFE$30.02-0.40(-1.31%)Pfizer's 25-Valent Pediatric Pneumococcal Conjugate Vaccine Candidate Shows Robust Phase 2 Data at IDWeek 2026[11:18:00 AM ET]BIVI$1.24-0.04(-3.13%)From Private Credit to Fusion Power: New to The Street Show #777 Premieres Tonight on Bloomberg Television[10:30:00 AM ET]AMGN$439.26-8.02(-1.79%)IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER Amgen (NASDAQ:AMGN) today announced landmark interim Phase 3 results showing that IMDELLTRA® (tarlatamab-dlle) in combination with AstraZeneca's...[10:30:00 AM ET]JNJ$263.81-3.80(-1.42%)Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk prostate cancer Johnson & Johnson (NYSE: JNJ) today announced new results from the Phase 3 PROTEUS substudy that directly compared the investigational use of...[8:54:00 AM ET]PBLS$24.79-2.13(-7.91%)Parabilis Medicines Presents Updated Phase 1/2 Data for Zolucatetide Demonstrating Compelling Efficacy and Favorable Safety and Tolerability Profile in Patients with Desmoid Tumors[8:45:00 AM ET]SMTC$131.80+6.68(+5.34%)Semtech Brings 5G Network Slicing, FIPS 140-3 to IACP 2026[8:00:00 AM ET]GMAB$43.85+3.85(+9.63%)Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer[7:00:00 AM ET]INCY$115.00-1.93(-1.65%)Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer[7:00:00 AM ET]NBTX$29.36+0.17(+0.58%)NANOBIOTIX Announces Final Data from Phase 1 Study Evaluating JNJ-1900 (NBTXR3) With Immune Checkpoint Inhibitors as a 2L+ Therapy in Anti-PD-1-Resistant Primary Cutaneous Melanoma[7:00:00 AM ET]

PBLS · NASDAQ

Parabilis Medicines, Inc.

$24.79 -2.46 (-9.12%)

Company overview

Fog Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops cell-penetrating miniproteins (CPMPs), which are specifically designed to target cancer-causing proteins inside cancer cells and neutralize them. The company was founded by Gregory L. Verdine, WeiQing Zhou and David Philip Lane in 2015 and is headquartered in Cambridge, MA.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$3B
Employees
145
Headquarters
Cambridge, MA
Website
parabilismed.com
CEO
Mathai Mammen
Listed
June 10, 2026
P/E
0.00
Dividend yield
0.00%

Price chart

21.8727.2232.5737.9343.28
PBLS 1D NASDAQ O26.74H26.74L23.96C24.44-2.48 (-9.21%)Vol1.82M

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
Ticker Type Headline Source Published
PBLS Stock news Parabilis Highlights 72% Response Rate, Maps Phase III Desmoid Trial for 2027 MarketBeat
PBLS Press release Parabilis Medicines Presents Updated Phase 1/2 Data for Zolucatetide Demonstrating Compelling Efficacy and Favorable Safety and Tolerability Profile in Patients with Desmoid Tumors GlobeNewswire
PBLS Stock news Silence Therapeutics, Disc Medicine, Veradermics And Other Big Stocks Moving Higher On Monday Benzinga
PBLS Press release Parabilis Medicines to Present Updated Clinical Data for Zolucatetide in Patients with Desmoid Tumors at ESMO Congress 2026 GlobeNewswire
PBLS Press release Parabilis Medicines Initiates Dose-Ranging Clinical Study of Zolucatetide in Familial Adenomatous Polyposis GlobeNewswire
PBLS Press release Parabilis Medicines to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference GlobeNewswire
PBLS Press release Parabilis Medicines Appoints Accomplished Drug Development Leader Craig L. Tendler, M.D. GlobeNewsWire
PBLS Stock news Parabilis Medicines: A Rare-Tumor Validation Ladder For An Undruggable Platform Seeking Alpha
PBLS Press release Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates GlobeNewsWire
See more
FAQ

Questions about Parabilis Medicines, Inc.

What does Parabilis Medicines, Inc. do?
Fog Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops cell-penetrating miniproteins (CPMPs), which are specifically designed to target cancer-causing proteins inside cancer cells and neutralize them. The company was founded by Gregory L. Verdine, WeiQing Zhou and David Philip Lane in 2015 and is headquartered in Cambridge, MA.
What is PBLS's market cap?
Parabilis Medicines, Inc. (PBLS) is a listed stock with a live quote. The latest market cap on this page is $3B.
Where is Parabilis Medicines, Inc. headquartered?
Parabilis Medicines, Inc. is headquartered in Cambridge, MA.
How do I get PBLS news from the API?
Call GET /v1/news?tickers=PBLS. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search the full archive in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees the full archive.
How far back does PBLS news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for PBLS, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees the full archive as headlines are ingested. A Free API key returns the last year. Pro keys search the full archive.
Is the PBLS price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 2,000 REST requests a day. Paid Pro removes the daily cap. If you don't subscribe, the account stays on Free.

Start 7-day free trial Read the docs